Prokinetic Agents: Drug Classes and GI Uses

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-09-20

Prokinetic agents are medications that increase or coordinate the muscular contractions of the gastrointestinal tract so that food, fluid, and gas move through it more normally. They are used for delayed transit problems such as delayed gastric emptying, postoperative ileus, and constipation, and some of them also control nausea and vomiting. This article covers the main drug classes used in dogs, cats, horses, cattle, and small mammals, the receptors they act on, the species where each one has evidence behind it, and the situations where giving a prokinetic can cause serious harm.

This article is educational and is not a substitute for veterinary diagnosis or treatment.

At a Glance

What Prokinetic Agents Are and What They Treat

The gut moves because smooth muscle in its wall contracts in coordinated waves. That movement is controlled by the enteric nervous system, a meshwork of nerve cells embedded in the gut wall, and by hormones and neurotransmitters that either excite or inhibit those nerves and muscles. A prokinetic agent is any drug that shifts this system toward more effective forward movement.

The term covers several different mechanisms. Some prokinetic medications work by blocking dopamine receptors, which removes a brake on gut motility. Others mimic serotonin at 5-HT4 receptors, which triggers acetylcholine release from enteric neurons and strengthens contractions. Others mimic motilin, a hormone that drives the migrating motor complex, the wave of activity that sweeps the fasting gut clean between meals.

Gastrointestinal motility disorders are the main reason these drugs are prescribed. These disorders include delayed transit, accelerated transit, impaired relaxation, and inappropriate relaxation [1]. Delayed transit is the most clinically important category in companion animals. It can affect the esophagus (hypomotility and megaesophagus), the stomach (delayed gastric emptying), the small intestine (postoperative ileus and intestinal pseudo-obstruction), or the colon (constipation and megacolon) [1]. Prokinetic agents are most useful when the problem is weak or uncoordinated contractions rather than a physical blockage.

In horses and cattle, the disorders that are thought to benefit from motility-restoring drugs include postoperative ileus and large colon impaction in horses, and displacement of the abomasum and dilatation of the cecum in cattle [2]. The same review notes that controlled experimental disease models for abomasal displacement in cattle are lacking, so conclusions about prokinetic benefit in that condition cannot be drawn from the available data [2].

How Prokinetic Agents Work: Receptor Targets

Metoclopramide

Metoclopramide is the most widely used prokinetic in small animal practice. It works through several receptors at once. It blocks dopamine D2 receptors, which removes dopaminergic inhibition of gastric and intestinal motility. It also acts as a 5-HT4 agonist, promoting acetylcholine release from myenteric neurons, and it blocks 5-HT3 receptors, which contributes to its antiemetic effect. The D2 blockade in the chemoreceptor trigger zone of the brain is the main reason it controls vomiting.

Metoclopramide's prokinetic effect is strongest in the upper gastrointestinal tract. It increases gastric emptying and antral contractions and improves coordination between the stomach and duodenum. Its effect on the lower gut is weaker and less predictable.

The evidence in dogs is mixed and dose-dependent. In a telemetry study of Beagles and Labrador Retrievers, low-dose metoclopramide (0.3 mg/kg) significantly increased the amplitude integral of antral contractions, while a higher dose (0.6 mg/kg) also increased pressure integrals but significantly less than the lower dose [3]. The same study found a clear breed difference: Labradors responded mainly at higher doses, and the pattern of response differed from Beagles [3].

In cats, metoclopramide has documented prokinetic activity. In a randomized, double-blind, four-way crossover study of eight healthy cats, the rate of solid-phase gastric emptying was significantly faster after metoclopramide than after placebo, and the total area under the motility index curve was significantly larger [4].

In horses, the picture is different. A study of seven healthy adult Thoroughbreds found that metoclopramide at 0.2 mg/kg improved jejunal motility but did not promote caecal motility [5]. An older study in ponies found that high doses of metoclopramide had only weak and unspecific stimulatory motor effects at the ileo-caeco-colonic junction [6]. A pharmacokinetic study in six adult horses found no clear trends in motility alteration after metoclopramide given as an intravenous constant rate infusion or subcutaneous bolus [7].

In pigeons, metoclopramide did not enhance upper gastrointestinal motility. In a randomized crossover study of 12 clinically healthy pigeons, metoclopramide did not produce faster transit or more frequent gastrointestinal contractions compared with saline, either in conscious birds or in birds with sedation-induced ileus [8].

Cisapride

Cisapride is a 5-HT4 agonist that promotes acetylcholine release from the myenteric plexus. It has a broader prokinetic profile than metoclopramide because it stimulates motility from the esophagus through the colon, rather than mainly the upper gut.

Cisapride was withdrawn from human markets in many countries because of cardiac arrhythmias, particularly QT prolongation and torsades de pointes. Veterinary use continues in some jurisdictions under restricted access, and it remains a subject of clinical study in animals.

The species differences are important. In dogs, cisapride increases antral motility. In the Beagle and Labrador telemetry study, low-dose cisapride (0.2 mg/kg) significantly increased the amplitude integral in Beagles, and higher doses also increased pressure integrals but less than the lower dose [3]. In cats, cisapride is used clinically for gastric emptying and colonic motility problems, though controlled feline gastric emptying data are more limited than for metoclopramide and erythromycin.

In horses, cisapride has documented activity. A study in ponies with implanted transducers found that cisapride produced marked and prolonged increases in electrical and mechanical activity at all sites examined, including the stomach, small intestine, left dorsal colon, and small colon [9]. Side effects observed included increased bowel sounds, increased frequency of defecation, and a slight increase in heart rate [9]. Another pony study found that cisapride induced migrating spike bursts in the colon associated with contractions of the caecal body and base, a pattern consistent with a true prokinetic effect at the ileo-caeco-colonic junction [6].

However, a later study in seven healthy adult Thoroughbreds found that cisapride at 1.0 mg/kg improved jejunal motility but did not promote caecal motility, and the authors concluded that among the agents studied, only mosapride at 2.0 mg/kg promoted both jejunal and caecal motility in horses [5]. This apparent conflict with the earlier pony studies likely reflects differences in dose, formulation, route, and measurement technique.

In rabbits, cisapride had no effect on fecal production, food intake, urine production, or water intake compared with placebo at 24, 48, or 72 hours after a single oral dose of 0.5 mg/kg [10].

Erythromycin

Erythromycin is a macrolide antibiotic that also acts as a motilin receptor agonist. Motilin is a hormone released in the fasting state that triggers the migrating motor complex, the cyclical wave of contractions that clears the stomach and small intestine between meals. By mimicking motilin, erythromycin accelerates gastric emptying and stimulates small intestinal motility.

Erythromycin's prokinetic effect is dose-dependent and can be lost at high doses, where the antibiotic effect predominates and the motilin-like effect may be overwhelmed. This is one reason it is used at lower doses for motility than for infection.

In cats, erythromycin has documented prokinetic activity. In the same four-way crossover study that tested metoclopramide, erythromycin significantly accelerated solid-phase gastric emptying compared with placebo, with significant differences at all fractions of the gastric emptying curve [4]. The total area under the motility index curve was also significantly larger after erythromycin than after placebo [4].

In horses, erythromycin is used clinically for postoperative ileus and other hypomotility states. The evidence base in horses is smaller than in small animals, but the drug is widely used in equine referral practice.

In cattle, erythromycin has documented contractile effects on bovine gastrointestinal smooth muscle. An in vitro study using isolated abomasal and duodenal specimens from routinely slaughtered cows confirmed the contractile effect of erythromycin when used alone [11]. The same study found that plant secondary metabolites such as saponins and flavonoids can modify this effect, with some compounds enhancing and others antagonizing the contractile response [11]. This is a reminder that diet and plant exposure can alter drug effects in ruminants.

Domperidone

Domperidone is a dopamine D2 antagonist that does not cross the blood-brain barrier readily, so it has less central antiemetic effect than metoclopramide but still promotes gastric emptying and upper gastrointestinal motility. It is used in dogs and cats for delayed gastric emptying and in horses for conditions such as fescue toxicosis, where it blocks dopamine receptors in the pituitary and helps restore normal prolactin and motility patterns.

Domperidone has a slower onset and longer duration than metoclopramide. It is available as an oral formulation. Veterinary-specific controlled studies of domperidone's prokinetic effects are limited compared with metoclopramide and cisapride, and much of the clinical use is based on extrapolation from mechanism and human data.

Mosapride

Mosapride is a 5-HT4 agonist that has been studied in horses. In the seven-horse study comparing mosapride, metoclopramide, cisapride, and lidocaine, mosapride at 1.0 mg/kg and 2.0 mg/kg facilitated gastric emptying, and mosapride at 2.0 mg/kg promoted both jejunal and caecal motility [5]. This makes mosapride the only agent in that study to improve motility in both the small intestine and the cecum. Mosapride is not approved for veterinary use in the United States, and its availability varies by country.

Other Agents

Several other drugs have prokinetic effects that are used in specific situations. Naloxone, an opioid antagonist, and neostigmine, an acetylcholinesterase inhibitor, are thought to restore motility of the large colon in cases of large colon impaction in horses [2]. Bethanechol and neostigmine significantly increase myoelectric activity of the cecum and proximal loop of the ascending colon in healthy cows [2]. Pyridostigmine, another acetylcholinesterase inhibitor, has been studied in rabbits but had no effect on fecal output or food intake [10]. Tegaserod, a 5-HT4 agonist, improved gastrointestinal transit time, bowel movements per day, and stool weight in horses in one study, with a greater acceleration of transit than cisapride [12].

Species Differences in Prokinetic Response

Species differences are not minor variations. They determine whether a drug works at all.

Dogs

Dogs respond to metoclopramide and cisapride, with dose-dependent and breed-dependent effects. The Beagle and Labrador study showed that low doses of both drugs increased antral motility amplitude integrals, and higher doses also increased pressure integrals but less than the lower doses [3]. This suggests that more is not always better, and that the dose-response curve for prokinetic effect is not linear.

Cats

Cats respond to metoclopramide and erythromycin for gastric emptying. The feline crossover study showed significant acceleration of solid-phase gastric emptying with both drugs compared with placebo [4]. Cisapride is used clinically in cats for gastric and colonic motility problems, though controlled feline gastric emptying data are more limited.

Horses

Horses are the species where prokinetic selection matters most. Metoclopramide improves jejunal motility but not caecal motility at the doses studied [5]. Cisapride has documented activity in ponies at multiple sites [6][9] but did not promote caecal motility in a later Thoroughbred study [5]. Mosapride at 2.0 mg/kg promoted both jejunal and caecal motility in the Thoroughbred study [5]. Erythromycin is used clinically for postoperative ileus. The choice of agent depends on which segment of the gut is hypomotile.

Cattle

Cattle respond to erythromycin with increased contractility of abomasal and duodenal smooth muscle in vitro [11]. Bethanechol and neostigmine increase myoelectric activity of the cecum and proximal loop of the ascending colon in healthy cows [2]. The evidence for prokinetic benefit in abomasal displacement is not conclusive because controlled experimental disease models are lacking [2].

Rabbits

Rabbits did not respond to metoclopramide, cisapride, pyridostigmine, or capromorelin with increased fecal output or food intake in a controlled crossover study [10]. This is important because rabbits are often presented with gastrointestinal stasis, and the assumption that prokinetics will help is not supported by this evidence.

Birds

Pigeons did not respond to metoclopramide with faster transit or more frequent contractions, even when sedation had slowed their gut [8]. This suggests that metoclopramide is not an effective prokinetic in this species.

Labeled Uses and What Prokinetic Agents Do Not Cover

Prokinetic agents are labeled or used for:

• Delayed gastric emptying
• Postoperative ileus
• Intestinal pseudo-obstruction
• Constipation and megacolon
• Nausea and vomiting (metoclopramide and domperidone)
• Large colon impaction in horses (naloxone, neostigmine)
• Cecal dilatation in cattle (bethanechol, neostigmine)

They do not cover:

• Mechanical obstruction. A prokinetic cannot move a physical blockage and may cause rupture.
• Perforation. Increasing motility when the gut wall is perforated can worsen contamination.
• Hemorrhage. Stimulating motility during active gastrointestinal bleeding can dislodge clots and worsen bleeding.
• Inflammatory or infectious diarrhea. Speeding transit may reduce fluid absorption and worsen dehydration.
• Painful conditions. Prokinetics do not treat pain and may increase discomfort if the gut is inflamed.

Contraindications: When Not to Give a Prokinetic

The core contraindications apply to all prokinetic agents:

• Gastrointestinal obstruction. Any mechanical blockage, whether from a foreign body, intussusception, or tumor, is an absolute contraindication. Increasing contractions against a fixed obstruction can cause perforation.
• Gastrointestinal perforation. If the gut wall is already breached, prokinetics can increase leakage of contents into the abdomen.
• Gastrointestinal hemorrhage. Active bleeding is a contraindication because increased motility can dislodge clots and worsen blood loss.

Additional contraindications are drug-specific:

• Metoclopramide should be avoided in animals with pheochromocytoma, seizure disorders, or known hypersensitivity to the drug. It can cause extrapyramidal signs, especially in young animals.
• Cisapride should be avoided in animals with known QT prolongation or cardiac disease, and in animals receiving other drugs that prolong the QT interval. It was withdrawn from human markets for this reason.
• Erythromycin should be avoided in animals with known macrolide hypersensitivity and used with caution in animals with liver disease.
• Domperidone should be avoided in animals with prolactin-secreting pituitary tumors and used with caution in animals with cardiac disease.

How Prokinetic Agents Are Given

Metoclopramide is available as oral tablets, oral solution, and injectable solution. In horses, it is often given as an intravenous constant rate infusion or subcutaneous bolus. A pharmacokinetic study in six adult horses found that subcutaneous bioavailability was estimated at 110 percent, and simulations suggested similar exposure between a 24-hour intravenous infusion and subcutaneous bolus regimens divided into three, four, or six doses per day [7].

Cisapride is given orally as a suspension or tablet. It is often compounded because commercial veterinary formulations are limited in some markets.

Erythromycin is given orally or intravenously. The intravenous route is used in horses for postoperative ileus.

Domperidone is given orally.

Mosapride is given orally.

The route matters for onset. Intravenous metoclopramide acts within minutes. Oral formulations take longer, depending on gastric emptying and absorption.

Side Effects and What to Do About Them

Prokinetic side effects fall into two categories: effects from the intended mechanism and effects from off-target actions.

Metoclopramide can cause:

• Extrapyramidal signs such as restlessness, muscle twitching, and abnormal postures, especially in young animals or after high doses.
• Drowsiness or excitement.
• Diarrhea from increased transit.

If extrapyramidal signs occur, stop the drug and contact a veterinarian. These signs are usually reversible.

Cisapride can cause:

• Increased bowel sounds and frequency of defecation [9].
• Slight increase in heart rate [9].
• Cardiac arrhythmias, particularly QT prolongation.

If arrhythmias are suspected, stop the drug and seek veterinary care immediately.

Erythromycin can cause:

• Nausea and vomiting.
• Diarrhea.
• Abdominal pain.
• Antibiotic-associated effects on gut flora.

Domperidone can cause:

• Increased prolactin levels.
• Diarrhea.
• Abdominal cramps.

Mosapride can cause:

• Diarrhea.
• Abdominal pain.

In horses, prokinetic side effects can include increased bowel sounds, increased defecation, and changes in heart rate [9]. These are usually mild but should be monitored.

Interactions

Prokinetic agents interact with other drugs in ways that matter clinically.

Metoclopramide interacts with:

• Anticholinergics such as atropine and glycopyrrolate, which oppose its prokinetic effect. A dog study found that atropine and glycopyrrolate completely inhibited gastric motility for at least 30 minutes at low doses and for more than 3 hours at higher doses [3].
• Opioids, which slow gut motility and oppose the prokinetic effect.
• Drugs that prolong the QT interval, because metoclopramide can add to this effect.

Cisapride interacts with:

• Drugs that inhibit cytochrome P450 3A4, which can increase cisapride levels and the risk of arrhythmias.
• Drugs that prolong the QT interval.
• Anticholinergics, which oppose its prokinetic effect.

Erythromycin interacts with:

• Drugs metabolized by cytochrome P450 3A4, because erythromycin inhibits this enzyme.
• Other QT-prolonging drugs.
• Plant secondary metabolites. An in vitro study in cattle found that saponins and flavonoids can enhance or antagonize erythromycin's contractile effect on bovine gastrointestinal smooth muscle [11].

Domperidone interacts with:

• Anticholinergics, which oppose its prokinetic effect.
• Drugs that prolong the QT interval.

How Prokinetic Agents Compare With Alternatives

Prokinetic agents are one option among several for managing gastrointestinal motility disorders. The alternatives include:

• Dietary management. Small, frequent meals and low-fat diets can reduce symptoms of delayed gastric emptying.
• Fluid therapy. Correcting dehydration and electrolyte imbalances can improve motility without drugs.
• Antiemetics. Drugs such as maropitant and ondansetron control nausea and vomiting without necessarily speeding transit.
• Analgesics. Pain can inhibit motility, so treating pain can improve gut function.
• Surgery. Mechanical obstruction, perforation, and some cases of megacolon require surgical correction rather than drugs.

The choice between prokinetic agents depends on the segment of the gut that is affected, the species, and the underlying cause. In horses, mosapride at 2.0 mg/kg promoted both jejunal and caecal motility, while metoclopramide and cisapride improved jejunal motility but not caecal motility in one study [5]. In cats, metoclopramide and erythromycin both accelerated gastric emptying [4]. In dogs, metoclopramide and cisapride increased antral motility, with dose-dependent and breed-dependent effects [3].

Clinical Relevance, Limitations and Common Mistakes

Prokinetic agents are not interchangeable. The receptor target determines which part of the gut is affected, and the species determines whether the drug works at all.

The most common mistake is giving a prokinetic when the gut is obstructed. This can cause perforation and death. Always confirm patency before starting a prokinetic.

The second most common mistake is assuming that a drug that works in one species will work in another. Metoclopramide does not enhance upper gastrointestinal motility in pigeons [8]. Metoclopramide, cisapride, pyridostigmine, and capromorelin do not increase fecal output or food intake in healthy rabbits [10]. Cisapride and metoclopramide improve jejunal motility but not caecal motility in horses at the doses studied [5]. These are not minor differences. They determine whether the drug will help or simply add side effects.

The third mistake is using a prokinetic as a substitute for treating the underlying cause. Delayed gastric emptying can be caused by pancreatitis, foreign body, metabolic disease, or drugs. A prokinetic may improve signs without addressing the cause.

The fourth mistake is ignoring drug interactions. Anticholinergics, opioids, and QT-prolonging drugs can all reduce the benefit or increase the risk of prokinetic therapy.

The fifth mistake is assuming that more drug means more effect. In dogs, higher doses of metoclopramide and cisapride increased pressure integrals but significantly less than lower doses [3]. The dose-response curve is not linear.

Individual cases need a veterinarian. The information here is a guide to the pharmacology, not a treatment plan.

Frequently Asked Questions

What are prokinetic agents used for?

Prokinetic agents are used for delayed gastric emptying, postoperative ileus, intestinal pseudo-obstruction, constipation, megacolon, and some cases of nausea and vomiting. They increase or coordinate gut contractions so that contents move more normally.

Do prokinetic medications work in all species?

No. Metoclopramide does not enhance upper gastrointestinal motility in pigeons [8], and metoclopramide, cisapride, pyridostigmine, and capromorelin do not increase fecal output or food intake in healthy rabbits [10]. Species differences are a core part of prokinetic pharmacology.

Can I give my pet a prokinetic if I think it has a blockage?

No. Gastrointestinal obstruction is an absolute contraindication to prokinetic therapy. Giving a prokinetic when the gut is blocked can cause perforation. Confirm patency with a veterinarian before starting any prokinetic.

Which prokinetic is best for horses?

It depends on which segment of the gut is hypomotile. Mosapride at 2.0 mg/kg promoted both jejunal and caecal motility in one study, while metoclopramide and cisapride improved jejunal motility but not caecal motility at the doses studied [5]. Erythromycin is also used clinically for postoperative ileus.

Does cisapride cause heart problems?

Cisapride was withdrawn from human markets in many countries because of cardiac arrhythmias, particularly QT prolongation and torsades de pointes. It should be avoided in animals with known QT prolongation or cardiac disease and in animals receiving other QT-prolonging drugs.

How does erythromycin work as a prokinetic?

Erythromycin is a macrolide antibiotic that also acts as a motilin receptor agonist. Motilin triggers the migrating motor complex, the wave of contractions that clears the fasting gut. By mimicking motilin, erythromycin accelerates gastric emptying and stimulates small intestinal motility.

What should I do if my pet has side effects from a prokinetic?

Stop the drug and contact a veterinarian. Extrapyramidal signs from metoclopramide are usually reversible. Cardiac signs from cisapride require immediate veterinary care. Diarrhea and abdominal discomfort from any prokinetic should be reported to the prescribing veterinarian.

Can prokinetics be used with other medications?

Yes, but interactions matter. Anticholinergics and opioids oppose the prokinetic effect. Erythromycin inhibits cytochrome P450 3A4 and can increase levels of other drugs. Cisapride and metoclopramide can add to the QT-prolonging effects of other drugs. Always tell the veterinarian about every medication the animal is receiving.

Related Articles

• Veterinary Pharmacology Drug Classes: A NAVLE Review
• Drug Interactions with Antithrombotic and Antiplatelet Agents in Veterinary Patients
• Drug Interactions with Chemotherapeutic Agents in Veterinary Oncology: A Practical Guide
• Drug Interactions with Antiviral Agents in Veterinary Patients: Current Knowledge and Gaps
• Drug Interactions with Immunosuppressive Agents in Veterinary Patients: Cyclosporine, Azathioprine, and More
• Dog Ear Cleaning Solution with Drying Agent: How to Use
• Ranitidine in Veterinary Medicine: Uses and Dosing
• Medication for Collapsing Trachea in Dogs: Drug Guide

Sources

1. Gastrointestinal motility disorders and gastrointestinal prokinetic therapy.
2. Drugs coordinating and restoring gastrointestinal motility and their effect on selected hypodynamic gastrointestinal disorders in horses and cattle.
3. Effect of anticholinergics (atropine, glycopyrrolate) and prokinetics (metoclopramide, cisapride) on gastric motility in beagles and labrador retrievers.
4. Ultrasonographic assessment of the effect of metoclopramide, erythromycin, and exenatide on solid-phase gastric emptying in healthy cats.
5. Effects of mosapride citrate, metoclopramide hydrochloride, lidocaine hydrochloride, and cisapride citrate on equine gastric emptying, small intestinal and caecal motility.
6. Prokinetic effects of cisapride, naloxone and parasympathetic stimulation at the equine ileo-caeco-colonic junction.
7. Evaluation of pharmacokinetics of metoclopramide administered via subcutaneous bolus and intravenous constant rate infusion to adult horses.
8. Metoclopramide does not enhance upper gastrointestinal motility in clinically healthy pigeons (Columba livia domestica) or those with sedation-induced functional ileus.
9. Actions of the novel gastrointestinal prokinetic agent cisapride on equine bowel motility.
10. The 4 prokinetic drugs metoclopramide, cisapride, pyridostigmine, and capromorelin do not increase fecal output or food intake in healthy New Zealand rabbits (Oryctolagus cuniculus).
11. Interactions between erythromycin, flunixin meglumine, levamisole and plant secondary metabolites towards bovine gastrointestinal motility-in vitro study.
12. Comparative Efficacy of the Prokinetic Effects of Cisapride and Tegaserod in Equines.